#Germany #Petah Tikva #Isotopia #DSD Pharma #Isoprotrace

Isotopia Launches Isoprotrace® in Germany

On March 10, 2025, Isotopia, a prominent player in the field of radiopharmaceuticals, announced the official launch of its cutting-edge product, Isoprotrace®, in Germany. This venture marks a significant milestone for the company as it partners with DSD Pharma, an established pharmaceutical distributor in the region, to facilitate the distribution of Isoprotrace® across hospitals, clinics, and diagnostic centers. This strategic collaboration is not just limited to Isoprotrace®, but also encompasses the distribution of Lutetium (177 Lu) Chloride n.c.a., further strengthening their offerings for cancer diagnostics and treatments in the market.

Isoprotrace® is an innovative radiopharmaceutical specifically designed for prostate cancer imaging. It features a multi-dose kit that enables the swift and efficient preparation of Gallium (68Ga) Gozetotide solution for intravenous use. Following radiolabelling with gallium (68Ga) chloride solution, Isoprotrace® is indicated for positron emission tomography (PET) in identifying prostate-specific membrane antigen (PSMA)-positive lesions. The clinical scenarios for its use include:

1. Primary staging of high-risk prostate cancer patients before initiating curative therapy.
2. Investigating suspected recurrence of prostate cancer in patients with elevated serum prostate-specific antigen (PSA) levels post curative therapy.

Prostate cancer remains a pressing health challenge, with over 70,000 new cases diagnosed every year in Germany. The importance of precise imaging is paramount in achieving accurate diagnoses and formulating effective treatment plans for affected individuals.

Tzachi Levy, General Manager of Isotopia's aseptic plant, expressed enthusiasm about the collaboration: "Germany is a key market for Isoprotrace®, and we believe that our partnership with DSD Pharma will facilitate a successful introduction and widespread accessibility of this innovative product for healthcare professionals throughout the country."

Dr. Susanne Dorudi, Managing Director at DSD Pharma, echoed this sentiment by stating, "We are honored to collaborate with Isotopia to introduce Isoprotrace® to the German market. This partnership provides German healthcare professionals with a groundbreaking option for imaging prostate cancer, and we are enthusiastic about the potential impact of this product."

Isoprotrace® has already received regulatory approval in the Netherlands and is expected to be launched in more than 10 EU countries soon. Isotopia has established a robust supply chain and a proven compliance record, showcasing its dedication to enhancing patient access to its innovative radiopharmaceuticals.

About Isotopia

Isotopia is renowned for its pioneering work in the development of radiopharmaceuticals aimed at molecular imaging and therapy. The company is committed to advancing patient care through precision medicine and delivering high-quality healthcare solutions.

About DSD Pharma

DSD Pharma is a well-respected distributor of pharmaceuticals in Austria, Germany, and Switzerland. With expertise in delivering advanced healthcare products, DSD Pharma collaborates with global leaders to ensure that cutting-edge solutions reach the market effectively.

In summary, the launch of Isoprotrace® in partnership with DSD Pharma represents a promising leap forward in prostate cancer imaging, with the potential to significantly improve patient outcomes.